ARTICLE | Clinical News

Symlin pramlintide: AMLN plans to run a double-blind, placebo-controlled dose titration study in 250 patients with Type I diabetes who are actively trying to im

January 7, 2002 8:00 AM UTC

The dose titration study, which is expected to start this quarter, will evaluate safety, HbA1c levels and insulin usage. Patients will receive 1 month of Symlin dose titration and insulin adjustment. ...